United States Steel Corporation (NYSE:X) and Nippon Steel are once again in active discussions to push forward their $55-per-share acquisition deal, according to new reports. The Japanese steelmaker is considering billions in additional investment to address US political concerns, sources familiar with the talks told Semafor.

Jim Cramer discusses Lululemon share tumble on its weak guidance.

Here we present three semiconductor stocks, CRDO, AVGO and MRVL, which are poised to benefit from a robust demand environment in the data center market.

Investors need to pay close attention to Blue Bird (BLBD) stock based on the movements in the options market lately.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=139463&wire=1 or contact Joseph E. Levi, Esq.

CGBD's merger with Carlyle Secured Lending and CSL III signifies a strategic alignment that is likely to enhance operational efficiency and minimize costs.

SNX's first-quarter fiscal 2025 results show modest revenue growth, but rising expenses and weak guidance trigger a sharp decline in its stock price.

On Thursday, stocks of car rental companies Hertz and Avis saw their values unexpectedly take off. As of midday, shares of Hertz Global Holdings were trading at around $4.15, an intraday increase of more than 20%.

LOS ANGELES , March 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ: GERN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 7, 2024 and February 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 12, 2025.

Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments.

Bitfarms has shifted from Bitcoin mining to an "energy and compute company," aiming to leverage its electrical capacity for AI data centers. Despite $135M in liquidity, capital expenditures make cash burn a concern, necessitating successful revenue generation from new ventures. The company's transformation introduces speculative risks, including potential share dilution and dependency on BTC pricing for the current operation.

The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.

Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.

Making predictions is notoriously tricky, even more so when trying to pinpoint where a leading cryptocurrency known for its volatility will be five years from now. Instead of trying to guess what Bitcoin's (BTC -0.79%) value will be in the future, a better approach might be to look at what could push its price higher -- and what might cause it to fall.

The technology-oriented Nasdaq 100 index is back into correction territory, down 10.5% after hitting an all-time high last month.

Maroussi, Greece – March 28, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), an international shipping company, announced today that its Annual Report on Form 20-F for the year ended December 31, 2024 has been filed with the Securities and Exchange Commission and can be accessed on our website, www.pyxistankers.com. Alternatively, shareholders may also request a hard copy of the annual report containing our audited financial statements, free of charge, by contacting us using the contact details provided at the end of this press release.

China Automotive Systems, Inc. (NASDAQ:CAAS ) Q4 2024 Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Kevin Theiss - IR Jie Li - CFO Conference Call Participants Operator Good morning, everyone. And welcome to the China Automotive Systems Fourth Quarter and Fiscal Year 2024 Conference Call.

LOS ANGELES , March 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Digimarc Corporation ("Digimarc" or "the Company") (NASDAQ: DMRC) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 2, 2024 and February 26, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 9, 2025.

LOS ANGELES , March 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against enCore Energy Corp. ("enCore" or "the Company") (NASDAQ: EU) for violations of the federal securities laws. Shareholders who purchased the Company's securities between March 28, 2024 and March 2, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 13, 2025.

LOS ANGELES , March 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Fluence Energy, Inc. ("Fluence" or "the Company") (NASDAQ: FLNC) for violations of the federal securities laws. Shareholders who purchased the Company's securities between November 29, 2023, and February 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 12, 2025.